POC(Point-of-Care) 진단 시장 예측(-2030년) : 제품 유형, 플랫폼, 처방, 샘플, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Point-of-Care Diagnostics Market is accounted for $33.4 billion in 2024 and is expected to reach $53.5 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Point-of-Care (POC) Diagnostics are medical testing conducted at or near the site of patient care. This approach allows for rapid diagnosis and immediate treatment, enhancing patient outcomes and reducing the need for follow-up visits. POC diagnostics encompass a range of tests, including blood glucose monitoring, pregnancy tests, infectious disease detection, and cardiac markers. The technology used in POC diagnostics is designed to be user-friendly, often requiring minimal training for healthcare providers or even patients. These tests provide quick results, which are crucial in critical care settings, remote locations, and in managing chronic diseases. The convenience and speed of POC diagnostics help in making informed clinical decisions promptly, thus improving the efficiency of healthcare delivery.

According to 2021 data published by the Centers for Disease Control and Prevention (CDC), there are approximately 38.4 million people with diabetes in the U.S.

Market Dynamics:

Driver:

Rising prevalence of chronic and infectious diseases

Chronic diseases like diabetes, cancer, and heart disease are becoming increasingly common around the world, due to factors like aging populations, unhealthy lifestyles, and environmental changes. POC tests can help with early detection and management of these conditions. Infectious diseases like COVID-19, HIV, and tuberculosis are also a major driver, as POC tests enable rapid diagnosis and intervention which boosts the growth of the market.

Restraint:

Strict regulatory requirements

Strict regulatory requirements often involve rigorous testing, documentation, and approval processes that can be time-consuming and costly. Consequently, companies may face delays in bringing new POC diagnostic devices to market, hindering innovation and reducing the speed at which advancements can benefit patients. The high costs associated with meeting regulatory standards can be particularly challenging for smaller companies and startups, potentially limiting their ability to compete and stifling diversity in the market.

Opportunity:

Shift towards decentralized healthcare

Decentralized healthcare model emphasizes providing medical care closer to the patient, outside traditional hospital settings. As a result, the demand for rapid, portable, and easy-to-use diagnostic tools has surged. POC diagnostics enable immediate testing and decision-making at the patient's location, be it a home, clinic, or remote area, aligning perfectly with the goals of decentralized healthcare. This shift enhances accessibility to diagnostic services, especially in underserved and rural areas, reducing the need for extensive lab infrastructure.

Threat:

Accuracy and reliability concerns

POC diagnostic tools sometimes exhibit variability in results compared to traditional laboratory tests. This discrepancy can undermine healthcare professionals' and patients' confidence in these tools, leading to reluctance in their widespread adoption. Inaccurate or inconsistent results can result in misdiagnoses, inappropriate treatment plans, and ultimately poorer patient outcomes, which are critical concerns in medical practice. Moreover, healthcare providers may require additional confirmatory tests from centralized laboratories to verify POC results, counteracting the primary advantage of rapid diagnosis.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the Point-of-Care (POC) Diagnostics market. The urgent need for rapid, accurate, and accessible testing solutions led to an unprecedented surge in demand for POC diagnostic tools. Governments and healthcare systems globally prioritized POC tests for quick detection and monitoring of the virus, accelerating innovation and adoption of these technologies. Regulatory bodies also expedited approval processes, allowing for faster market entry. However, supply chain disruptions and the intense focus on Covid-19 diagnostics temporarily overshadowed the development and availability of POC tests for other conditions.

The glucose monitoring kits segment is expected to be the largest during the forecast period

The glucose monitoring kits is expected to be the largest during the forecast period as these kits, essential for diabetes management, exemplify the benefits of POC diagnostics, enabling real-time monitoring and immediate decision-making for patients. Their widespread adoption has driven technological advancements and consumer acceptance in the POC market. Moreover, the success of glucose monitoring kits has spurred innovation and investment in developing similar POC diagnostic tools for other chronic conditions, thereby expanding the market and improving overall healthcare delivery.

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period because these advanced techniques allow for the rapid identification of genetic material from pathogens, leading to precise diagnostics for infectious diseases, genetic disorders, and cancer. The integration of molecular diagnostics into POC settings has driven innovation, resulting in portable, user-friendly devices capable of delivering lab-quality results quickly. This advancement has expanded the applications of POC diagnostics, improved patient outcomes through timely intervention.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to high prevalence of chronic diseases, an aging population, and a strong emphasis on early diagnosis and personalized medicine. The region benefits from advanced healthcare infrastructure, significant healthcare expenditure, and robust research and development activities. Moreover in the United States and Canada, there is a strong adoption of POC diagnostics in various settings, including hospitals, clinics, and home care. The Covid-19 pandemic further accelerated the demand for rapid and accurate POC testing, highlighting its importance in managing public health emergencies drives the market growth in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period because regulatory bodies like the FDA play a crucial role in shaping the market by ensuring the safety and efficacy of POC diagnostic devices. Additionally, technological advancements, such as the integration of artificial intelligence and mobile health technologies, are driving innovation and expanding the capabilities of POC diagnostics.

Key players in the market

Some of the key players in Point-of-Care Diagnostics market include Abbott, AccuBioTech Co., Ltd, Anbio Biotechnology Co., Ltd., Becton, Dickinson and Company, bioMerieux S.A., Chembio Diagnostics, Danaher Corporation, EKF Diagnostics, F. Hoffman-La Roche Ltd., Instrumentation Laboratory, Nova Biomedical, Orasure Technologies, Inc., PTS Diagnostics, Qiagen, Sekisui Diagnostics, Siemens Healthineers AG, Thermo Fisher Scientific, Trinity Biotech and Werfen

Key Developments:

In June 2024, Abbott and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative.

In June 2024, BD (Becton, Dickinson and Company) and Edwards Lifesciences today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

In March 2024, Abbott, Real Madrid and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 seasons. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.

Product Types Covered:

• Glucose Monitoring Kits
• Infectious Disease Testing Kits
• Hematology Testing Kits
• Cholesterol Testing Kits
• Pregnancy and Fertility Testing Kits
• Coagulation Monitoring Kit
• Urinalysis Testing Kits
• Drug Abuse Testing Kits
• Cardiac Markers
• Thyroid Stimulating Hormone Testing
• Blood Gas/Electrolytes
• Other Product Types

Platforms Covered:

• Dipsticks
• Lateral Flow Assays
• Microfluidics
• Molecular Diagnostics
• Immunoassays
• Other Platforms

Prescriptions Covered:

• Prescription Based
• Over The Counter Testing

Samples Covered:

• Blood
• Nasal & Oropharyngeal Swabs
• Urine
• Other Samples

Applications Covered:

• Infectious Diseases
• Cardiology
• Diabetes
• Oncology
• Hematology
• Pregnancy & Fertility
• Cholesterol
• Other Applications

End Users Covered:

• Hospitals
• Clinics & Ambulatory Care Centers
• Home Care Settings
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Point-of-Care Diagnostics Market, By Product Type

• 5.1 Introduction
• 5.2 Glucose Monitoring Kits
• 5.3 Infectious Disease Testing Kits
• 5.4 Hematology Testing Kits
• 5.5 Cholesterol Testing Kits
• 5.6 Pregnancy and Fertility Testing Kits
• 5.7 Coagulation Monitoring Kit
• 5.8 Urinalysis Testing Kits
• 5.9 Drug Abuse Testing Kits
• 5.10 Cardiac Markers
• 5.11 Thyroid Stimulating Hormone Testing
• 5.12 Blood Gas/Electrolytes
• 5.13 Other Product Types

6 Global Point-of-Care Diagnostics Market, By Platform

• 6.1 Introduction
• 6.2 Dipsticks
• 6.3 Lateral Flow Assays
• 6.4 Microfluidics
• 6.5 Molecular Diagnostics
• 6.6 Immunoassays
• 6.7 Other Platforms

7 Global Point-of-Care Diagnostics Market, By Prescription

• 7.1 Introduction
• 7.2 Prescription Based
• 7.3 Over The Counter Testing

8 Global Point-of-Care Diagnostics Market, By Sample

• 8.1 Introduction
• 8.2 Blood
• 8.3 Nasal & Oropharyngeal Swabs
• 8.4 Urine
• 8.5 Other Samples

9 Global Point-of-Care Diagnostics Market, By Application

• 9.1 Introduction
• 9.2 Infectious Diseases
• 9.3 Cardiology
• 9.4 Diabetes
• 9.5 Oncology
• 9.6 Hematology
• 9.7 Pregnancy & Fertility
• 9.8 Cholesterol
• 9.9 Other Applications

10 Global Point-of-Care Diagnostics Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Clinics & Ambulatory Care Centers
• 10.4 Home Care Settings
• 10.5 Diagnostic Laboratories
• 10.6 Academic & Research Institutes
• 10.7 Pharmacies
• 10.8 Other End Users

11 Global Point-of-Care Diagnostics Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott
• 13.2 AccuBioTech Co., Ltd
• 13.3 Anbio Biotechnology Co., Ltd.
• 13.4 Becton, Dickinson and Company
• 13.5 bioMerieux S.A.
• 13.6 Chembio Diagnostics
• 13.7 Danaher Corporation
• 13.8 EKF Diagnostics
• 13.9 F. Hoffman-La Roche Ltd.
• 13.10 Instrumentation Laboratory
• 13.11 Nova Biomedical
• 13.12 Orasure Technologies, Inc.
• 13.13 PTS Diagnostics
• 13.14 Qiagen
• 13.15 Sekisui Diagnostics
• 13.16 Siemens Healthineers AG
• 13.17 Thermo Fisher Scientific
• 13.18 Trinity Biotech
• 13.19 Werfen